ANTICA 201
Alternative Names: ANTICA-201Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Protheragen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 Sep 2020 ANTICA 201 is available for licensing as of 08 Sep 2020. https://www.protheragen.com/available-projects/antica-201/
- 08 Sep 2020 Protheragen has patent protection for ANTICA 201 (Protheragen pipeline, September 2020)